X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs IPCA LABS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA IPCA LABS SUN PHARMA/
IPCA LABS
 
P/E (TTM) x 25.9 41.9 61.7% View Chart
P/BV x 3.8 3.2 117.6% View Chart
Dividend Yield % 0.6 0.2 380.5%  

Financials

 SUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
IPCA LABS
Mar-17
SUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs842643 131.0%   
Low Rs572503 113.8%   
Sales per share (Unadj.) Rs131.6254.4 51.7%  
Earnings per share (Unadj.) Rs32.716.1 203.5%  
Cash flow per share (Unadj.) Rs38.029.8 127.5%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.50.2 283.5%  
Book value per share (Unadj.) Rs152.7194.6 78.5%  
Shares outstanding (eoy) m2,399.26126.20 1,901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.42.3 238.6%   
Avg P/E ratio x21.635.7 60.7%  
P/CF ratio (eoy) x18.619.2 96.8%  
Price / Book Value ratio x4.62.9 157.3%  
Dividend payout %10.76.2 172.0%   
Avg Mkt Cap Rs m1,696,87772,300 2,347.0%   
No. of employees `00017.513.3 131.7%   
Total wages/salary Rs m49,0236,960 704.4%   
Avg. sales/employee Rs Th18,028.32,413.5 747.0%   
Avg. wages/employee Rs Th2,798.8523.2 535.0%   
Avg. net profit/employee Rs Th4,479.5152.4 2,938.4%   
INCOME DATA
Net Sales Rs m315,78432,106 983.6%  
Other income Rs m6,232226 2,761.0%   
Total revenues Rs m322,01632,332 996.0%   
Gross profit Rs m100,8934,448 2,268.4%  
Depreciation Rs m12,6481,730 731.3%   
Interest Rs m3,998241 1,660.3%   
Profit before tax Rs m90,4792,703 3,347.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116675 1,794.4%   
Profit after tax Rs m78,4622,028 3,868.9%  
Gross profit margin %31.913.9 230.6%  
Effective tax rate %13.425.0 53.6%   
Net profit margin %24.86.3 393.4%  
BALANCE SHEET DATA
Current assets Rs m329,53717,340 1,900.5%   
Current liabilities Rs m178,8709,559 1,871.2%   
Net working cap to sales %47.724.2 196.9%  
Current ratio x1.81.8 101.6%  
Inventory Days Days79100 78.7%  
Debtors Days Days8357 146.4%  
Net fixed assets Rs m204,76620,779 985.4%   
Share capital Rs m2,399252 950.6%   
"Free" reserves Rs m363,99724,499 1,485.8%   
Net worth Rs m366,39724,553 1,492.3%   
Long term debt Rs m14,3613,517 408.3%   
Total assets Rs m614,10239,595 1,551.0%  
Interest coverage x23.612.2 193.3%   
Debt to equity ratio x00.1 27.4%  
Sales to assets ratio x0.50.8 63.4%   
Return on assets %13.45.7 234.3%  
Return on equity %21.48.3 259.3%  
Return on capital %24.810.5 236.8%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m44,11815,617 282.5%   
Fx outflow Rs m24,4845,828 420.1%   
Net fx Rs m19,6349,790 200.6%   
CASH FLOW
From Operations Rs m70,8222,764 2,562.1%  
From Investments Rs m-42,216-1,432 2,948.7%  
From Financial Activity Rs m-22,854-1,591 1,436.2%  
Net Cashflow Rs m6,107-259 -2,359.6%  

Share Holding

Indian Promoters % 63.7 45.9 138.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.4 45.0%  
FIIs % 23.0 25.3 90.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.4 47.7%  
Shareholders   133,026 36,892 360.6%  
Pledged promoter(s) holding % 0.5 2.1 24.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  CIPLA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS